Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 6Ovarian Neoplasms 4Neurofibrosarcoma 3Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Dermatofibrosarcoma 2Vascular Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Tumor, Adult 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Relapsed Pediatric Solid Tumor 1Refractory or Recurrent Solid Tumor 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Liposarcoma, Myxoid 1Liposarcoma 1Histiocytoma, Angiomatoid Fibrous 1Histiocytoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1

Interventions

pazopanib 1lentiviral minigene vaccine of COVID-19 coronavirus 1Docetaxel 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Histiocytoma × pazopanib × Clear all
NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
5 enrolled 6 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡